---
document_datetime: 2025-01-21 17:59:29
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/bortezomib-sun-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: bortezomib-sun-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 17.1321142
conversion_datetime: 2025-12-17 15:17:55.012193
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Bortezomib SUN

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0024               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                   | 20/01/2025                          |                                             | PL                               |           |
| II/0023              | B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms | 11/07/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   | manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                               |            |            |                     |                                                                                                                   |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-------------------------------------------------------------------------------------------------------------------|
| II/0022           | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                   | 01/02/2024 | n/a        |                     |                                                                                                                   |
| PSUSA/424/2 02304 | Periodic Safety Update EU Single assessment - bortezomib                                                                                                                                                                                                                                                                                                                      | 30/11/2023 | n/a        |                     | PRAC Recommendation - maintenance                                                                                 |
| IAIN/0021         | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                            | 16/10/2023 | n/a        |                     |                                                                                                                   |
| IB/0019/G         | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH A.6 - Administrative change - Change in ATC Code/ATC Vet Code | 31/08/2021 | 12/08/2022 | SmPC                |                                                                                                                   |
| IB/0018           | B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation                                                                                                                                                                                                                                                                           | 26/07/2021 | n/a        |                     |                                                                                                                   |
| IB/0017           | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                     | 26/07/2021 | 12/08/2022 | SmPC                |                                                                                                                   |
| R/0015            | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                       | 22/04/2021 | 21/06/2021 | SmPC, Labelling and | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of |

<div style=\"page-break-after: always\"></div>

|                   |                                                                                                                                                                                                                                                              |            |            | PL              | Bortezomib Sun in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/424/2 02004 | Periodic Safety Update EU Single assessment - bortezomib                                                                                                                                                                                                     | 10/12/2020 | 18/02/2021 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/424/202004.                     |
| IB/0016           | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                    | 14/12/2020 | 21/06/2021 | SmPC            |                                                                                                                                                              |
| N/0014            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 01/10/2020 | 18/02/2021 | PL              |                                                                                                                                                              |
| IB/0012           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 09/07/2020 | 18/02/2021 | Annex II and PL |                                                                                                                                                              |
| PSUSA/424/2 01904 | Periodic Safety Update EU Single assessment - bortezomib                                                                                                                                                                                                     | 28/11/2019 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                            |
| N/0011            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 30/08/2019 | 18/02/2021 | PL              |                                                                                                                                                              |
| IA/0010           | B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other changes to a test procedure (including replacement or addition)                                                                                            | 31/07/2019 | n/a        |                 |                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| PSUSA/424/2 01804   | Periodic Safety Update EU Single assessment - bortezomib                                                                                                                                                                                                                                | 13/12/2018   | 20/02/2019   | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/424/201804.   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| N/0007              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                        | 09/11/2018   | 20/02/2019   | PL                     |                                                                                                                                            |
| N/0005              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                        | 24/07/2018   | 20/02/2019   | PL                     |                                                                                                                                            |
| PSUSA/424/2 01704   | Periodic Safety Update EU Single assessment - bortezomib                                                                                                                                                                                                                                | 30/11/2017   | n/a          |                        | PRAC Recommendation - maintenance                                                                                                          |
| IB/0004             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                               | 07/09/2017   | 15/11/2017   | SmPC                   |                                                                                                                                            |
| IB/0002             | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                            | 06/07/2017   | 15/11/2017   | SmPC and PL            |                                                                                                                                            |
| IB/0001/G           | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the | 24/11/2016   | 15/11/2017   | SmPC, Labelling and PL |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>